188891-12-5

Basic information

• Product Name: Acetic acid, (4-acetyl-2-methoxyphenoxy)-, 1,1-dimethylethyl ester
• CAS NO: 188891-12-5
• Molecular Formula: C15H20O5
• Molecular Weight: 280.321
• Mol File: 188891-12-5.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Acetic acid, (4-acetyl-2-methoxyphenoxy)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, (4-acetyl-2-methoxyphenoxy)-, 1,1-dimethylethyl ester(188891-12-5)
• EPA Substance Registry System: Acetic acid, (4-acetyl-2-methoxyphenoxy)-, 1,1-dimethylethyl ester(188891-12-5)

Safety Data

• Hazardous Substances Data: 188891-12-5(Hazardous Substances Data)

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 498-02-2 1-(3-methoxy-4-hydroxyphenyl)ethanone 

Downstream Products

• 188891-17-0 N-benzyl-[4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy]acetamide 
• 188891-15-8 N-benzyl-(4-acetyl-2-methoxy-5-nitrophenoxy)acetamide 
• 188891-13-6 2-(4-acetyl-2-methoxy-5-nitrophenoxy)acetic acid 
• 1262298-73-6 2-(4-acetyl-2-methoxy-5-nitrophenoxy)-N-cyclododecylacetamide 
• 1262298-75-8 N-cyclododecyl-2-(4-(1-diazoethyl)-2-methoxy-5-nitrophenoxy)acetamide 
• 1262298-74-7 (E/Z)-N-cyclododecyl-2-(4-(1-hydrazonoethyl)-2-methoxy-5-nitrophenoxy)acetamide 
• 1425485-71-7 N-(2-{2-[2-(2-azido-ethoxy)ethoxy]ethoxy}ethyl)-2-[4-(1-diazo-ethyl)-2-methoxy-5-nitro-phenoxy]acetamide 

Relevant articles and documents

Light Control of Protein Solubility Through Isoelectric Point Modulation

We previously described the photoactivated depot or PAD approach that allows for the light control of therapeutic protein release. This approach relies on the ability to use light to change a protein's solubility. Traditionally this was accomplished by li

Photoactivatable Prodrug of Doxazolidine Targeting Exosomes

Natural lipid nanocarriers, exosomes, carry cell-signaling materials such as DNA and RNA for intercellular communications. Exosomes derived from cancer cells contribute to the progression and metastasis of cancer cells by transferring oncogenic signaling molecules to neighboring and remote premetastatic sites. Therefore, applying the unique properties of exosomes for cancer therapy has been expected in science, medicine, and drug discovery fields. Herein, we report that an exosome-targeting prodrug system, designated MARCKS-ED-photodoxaz, could spatiotemporally control the activation of an exquisitely cytotoxic agent, doxazolidine (doxaz), with UV light. The MARCKS-ED peptide enters a cell by forming a complex with the exosomes in situ at its plasma membrane and in the media. MARCKS-ED-photodoxaz releases doxaz under near-UV irradiation to inhibit cell growth with low nanomolar IC50 values. The MARCKS-ED-photodoxaz system targeting exosomes and utilizing photochemistry will potentially provide a new approach for the treatment of cancer, especially for highly progressive and invasive metastatic cancers.

ANTHRACYCLINE PRODRUGS AND METHODS OF MAKING AND USING THE SAME

Therapeutically effective prodrug compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of making and using these compounds.